ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 918,100 shares, an increase of 151.7% from the December 15th total of 364,700 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 0.6 days.

Analysts Set New Price Targets

PRQR has been the subject of a number of research analyst reports. Oppenheimer began coverage on ProQR Therapeutics in a research note on Friday. They issued an "outperform" rating and a $15.00 target price for the company. Chardan Capital reissued a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. JMP Securities reaffirmed a "market outperform" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, StockNews.com cut shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, November 28th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PRQR. OneDigital Investment Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock valued at $105,000 after buying an additional 15,550 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock valued at $107,000 after acquiring an additional 7,300 shares during the period. Finally, Privium Fund Management B.V. increased its stake in shares of ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock worth $10,251,000 after purchasing an additional 51,663 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Price Performance

PRQR stock traded down $0.01 during midday trading on Tuesday, hitting $2.26. The company's stock had a trading volume of 357,486 shares, compared to its average volume of 319,648. The company's fifty day moving average price is $3.18 and its 200 day moving average price is $2.53. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62. The stock has a market capitalization of $184.60 million, a P/E ratio of -7.06 and a beta of 0.30.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.